Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company's products are used in respiratory system, cardiovascular and cerebrovascular, respiratory, cardiovascular, and digestive systems. The company was formerly known as Guan...
Teyi Pharmaceutical Group reported revenue of 924.53 million CNY for fiscal year 2025, up 34.4% from fiscal year 2024, and net income of 81.67 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 209.87 million CNY, down 28.9% from a year before. Its largest business segment, Pharmaceutical Industry, brought in 98% of segment revenue in fiscal year 2025; South China was the largest region with 53%.
Figures from company filings; latest fiscal year ended December 31, 2025.
No profile data available.